HRP20230989T1 - Novi sastavi željeza i metode njihove izrade i upotrebe - Google Patents

Novi sastavi željeza i metode njihove izrade i upotrebe Download PDF

Info

Publication number
HRP20230989T1
HRP20230989T1 HRP20230989TT HRP20230989T HRP20230989T1 HR P20230989 T1 HRP20230989 T1 HR P20230989T1 HR P20230989T T HRP20230989T T HR P20230989TT HR P20230989 T HRP20230989 T HR P20230989T HR P20230989 T1 HRP20230989 T1 HR P20230989T1
Authority
HR
Croatia
Prior art keywords
composition
iron solution
use according
aqueous
aqueous iron
Prior art date
Application number
HRP20230989TT
Other languages
English (en)
Croatian (hr)
Inventor
Donald Jeffrey Keyser
Alvaro F. Guillem
Richard A. ZAGER
Original Assignee
Renibus Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Renibus Therapeutics, Inc. filed Critical Renibus Therapeutics, Inc.
Publication of HRP20230989T1 publication Critical patent/HRP20230989T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H23/00—Compounds containing boron, silicon or a metal, e.g. chelates or vitamin B12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/409—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/26—Iron; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
HRP20230989TT 2019-02-28 2020-02-28 Novi sastavi željeza i metode njihove izrade i upotrebe HRP20230989T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962812028P 2019-02-28 2019-02-28
PCT/US2020/020517 WO2020176894A1 (en) 2019-02-28 2020-02-28 Novel iron compositions and methods of making and using the same
EP20717359.2A EP3930686B1 (en) 2019-02-28 2020-02-28 Novel iron compositions and methods of making and using the same

Publications (1)

Publication Number Publication Date
HRP20230989T1 true HRP20230989T1 (hr) 2023-12-08

Family

ID=70190086

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20230989TT HRP20230989T1 (hr) 2019-02-28 2020-02-28 Novi sastavi željeza i metode njihove izrade i upotrebe

Country Status (20)

Country Link
US (4) US11292813B2 (OSRAM)
EP (2) EP4234020A3 (OSRAM)
JP (3) JP7320611B2 (OSRAM)
KR (1) KR20210133243A (OSRAM)
CN (2) CN113825496B (OSRAM)
AU (2) AU2020229381A1 (OSRAM)
CA (1) CA3131596A1 (OSRAM)
DK (1) DK3930686T3 (OSRAM)
ES (1) ES2955019T3 (OSRAM)
FI (1) FI3930686T3 (OSRAM)
HR (1) HRP20230989T1 (OSRAM)
HU (1) HUE063182T2 (OSRAM)
LT (1) LT3930686T (OSRAM)
PL (1) PL3930686T3 (OSRAM)
PT (1) PT3930686T (OSRAM)
RS (1) RS64652B1 (OSRAM)
SG (1) SG11202109323UA (OSRAM)
SI (1) SI3930686T1 (OSRAM)
SM (1) SMT202300276T1 (OSRAM)
WO (1) WO2020176894A1 (OSRAM)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2023002929A (es) * 2020-09-11 2023-05-22 Renibus Therapeutics Inc Método para tratamiento del cáncer con protección renal.
WO2024069644A1 (en) * 2022-09-30 2024-04-04 West Bengal Chemical Industries Limited A pharmaceutically acceptable ferric carboxymaltose and preparation thereof
CN115969714B (zh) * 2022-11-03 2025-03-11 华熙生物科技股份有限公司 具有光谱选择性的防晒组合物及其应用
WO2025047574A1 (ja) 2023-08-29 2025-03-06 株式会社ダイセル 硬化性エポキシ組成物

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE862482C (de) * 1950-05-14 1953-01-12 Merck Chem Fab E Verfahren zur Darstellung haltbarer, injizierbarer Loesungen von Salzen des dreiwertigen Eisens
US5624668A (en) 1995-09-29 1997-04-29 Luitpold Pharmaceuticals, Inc. Iron dextran formulations
DE19547356A1 (de) 1995-12-19 1997-06-26 Vifor Int Ag Adsorbens für Phosphat aus wäßrigem Medium, dessen Herstellung und Verwendung
US20030232738A1 (en) * 1998-04-20 2003-12-18 National Jewish Medical And Research Center Method and composition for increasing CD4+ T lymphocyte immune responsiveness
CA2365787C (en) * 2000-12-20 2006-02-14 Dialysis Solutions Inc. Sterile low bicarbonate dialysis concentrate solutions
JP4408807B2 (ja) * 2002-08-26 2010-02-03 ヴァイフォー（インターナショナル）アーゲー 鉄含有処方の生物学的等価性試験
EP1733058B8 (en) * 2004-03-16 2012-10-24 Navinta LLC Iron sucrose complexes and method of manufacture thereof
US8030480B2 (en) 2004-12-06 2011-10-04 Emcure Pharmaceuticals Limited Cost-effective process for preparation of manufacture of iron sucrose
ITMO20050056A1 (it) 2005-03-15 2006-09-16 Biofer Spa Processo per la preparazione di complessi del ferro trivalente con zuccheri mono-, di- e polisaccaridi.
CN100528237C (zh) 2005-04-26 2009-08-19 重庆医药工业研究院有限责任公司 多核的氢氧化铁-糖复合物的制备方法
EP1757299A1 (de) 2005-08-25 2007-02-28 Vifor (International) Ag Eisen(III)-Komplexverbindungen zur Behandlung von Eisenmangel-Zuständen bei Patienten mit chronisch-entzündlicher Darmerkrankung
JP5524622B2 (ja) 2006-10-04 2014-06-18 インファケア ファーマスーティカル，コーポレイション スタンソポルフィンの高純度で大規模な製造
EP1947120A1 (de) 2007-01-19 2008-07-23 Vifor (International) Ag Eisen-Kohlenhydrat-Komplex-Verbindungen
IN269965B (OSRAM) 2007-06-25 2015-11-27 Claris Lifescienses Ltd
TWI468167B (zh) 2007-11-16 2015-01-11 威佛（國際）股份有限公司 藥學組成物
BRPI1009110A2 (pt) 2009-03-02 2019-09-24 Vifor Int Ag adsorvente de fosfato
CN102451185A (zh) 2010-10-19 2012-05-16 长春纳米生技公司 金属离子纳米簇组合物
EP2548562A1 (de) 2011-07-18 2013-01-23 SeBo GmbH Kombinationstherapie mit Eisen-basierenden Phosphatadsorbern
EP2647389A1 (en) * 2012-04-04 2013-10-09 Charité - Universitätsmedizin Berlin Magnetic nanoparticle dispersion, its preparation and diagnostic and therapeutic use
CN103340827B (zh) * 2013-07-16 2014-12-10 成都天台山制药有限公司 蔗糖铁注射液及其制法
CN104558064A (zh) 2013-10-29 2015-04-29 北京京卫信康医药科技发展有限公司 蔗糖铁的制备方法
IN2013CH05383A (OSRAM) 2013-11-21 2015-08-28 Reddy’S Lab Ltd Dr
CN104098616B (zh) 2014-05-27 2016-04-20 广西壮族自治区化工研究院 一种蔗糖铁的制备方法
CN107072190B (zh) 2014-09-29 2020-10-09 弗莱德哈钦森癌症研究中心 使用应激蛋白质诱导剂诱导获得性细胞抗性的组合物、试剂盒及方法
WO2017165692A1 (en) * 2016-03-23 2017-09-28 Fred Hutchinson Cancer Research Center Compounds linked with a saccharide metal complex and uses thereof
US20190358242A1 (en) * 2017-02-08 2019-11-28 Fred Hutchinson Cancer Research Center Compositions, kits, and methods to induce acquired cytoresistance using stress protein inducers
SG11202001594TA (en) 2017-09-11 2020-03-30 Pharmacosmos Holding As Iron complex compounds for therapeutic use
CN109912675B (zh) 2017-12-13 2020-09-15 北京市林业果树科学研究院 一种蔗糖亚铁及其制备方法
CN110063965A (zh) 2019-06-04 2019-07-30 吉林省富生医疗器械有限公司 一种血液透析浓缩物
CN112315902B (zh) 2019-08-05 2022-05-13 南京恒生制药有限公司 一种低易变铁含量蔗糖铁注射液制备方法
CN112168844A (zh) 2020-09-29 2021-01-05 神奈纳米医药技术(珠海)有限公司 一种氢氧化铁碳水化合物复合物的制备方法
MX2023003647A (es) 2020-09-29 2023-06-09 Lg Bionano Llc Metodos para preparar complejos de hierro.
CN112156109A (zh) 2020-09-29 2021-01-01 神奈纳米医药技术(珠海)有限公司 氢氧化铁-糖络合物的制备方法及其应用
CN115531414A (zh) 2021-06-30 2022-12-30 南京恒生制药有限公司 一种新型蔗糖铁复合物及其制备方法
WO2023028252A1 (en) 2021-08-27 2023-03-02 American Regent, Inc. Iron compositions and methods of making and using them

Also Published As

Publication number Publication date
CN119488480A (zh) 2025-02-21
LT3930686T (lt) 2023-10-10
WO2020176894A1 (en) 2020-09-03
JP7320611B2 (ja) 2023-08-03
AU2020229381A1 (en) 2021-09-16
US20240002427A1 (en) 2024-01-04
AU2025230678A1 (en) 2025-10-02
HUE063182T2 (hu) 2024-01-28
SG11202109323UA (en) 2021-09-29
PL3930686T3 (pl) 2023-11-27
US20230070012A1 (en) 2023-03-09
SMT202300276T1 (it) 2023-11-13
EP3930686B1 (en) 2023-05-31
EP3930686A1 (en) 2022-01-05
PT3930686T (pt) 2023-09-04
JP2025084949A (ja) 2025-06-03
FI3930686T3 (fi) 2023-09-01
CN113825496A (zh) 2021-12-21
CN113825496B (zh) 2024-09-27
JP2023139154A (ja) 2023-10-03
US20220242901A1 (en) 2022-08-04
DK3930686T3 (da) 2023-09-11
US11292813B2 (en) 2022-04-05
US20200277325A1 (en) 2020-09-03
EP4234020A3 (en) 2023-10-04
SI3930686T1 (sl) 2023-11-30
US11840552B2 (en) 2023-12-12
CA3131596A1 (en) 2020-09-03
RS64652B1 (sr) 2023-10-31
JP7646750B2 (ja) 2025-03-17
EP4234020A2 (en) 2023-08-30
JP2022522009A (ja) 2022-04-13
US11834471B2 (en) 2023-12-05
ES2955019T3 (es) 2023-11-28
KR20210133243A (ko) 2021-11-05

Similar Documents

Publication Publication Date Title
JP2015164933A5 (OSRAM)
ME02520B (me) Farmaceutske kompozicije
HRP20230929T1 (hr) Stabilni pripravci semaglutida i njihova upotreba
RU2007111713A (ru) Фармацевтическая композиция для перорального введения в форме частиц с рассчитанным временем высвобождения и быстро распадающиеся таблетки, содержащие указанную композицию
RU2013103534A (ru) Лечение легочных инфекций с помощью введения тобрамицина путем аэролизации
CO6260019A2 (es) Metodos para el tratamiento de desordenes gastrointestinales independientes de la ingesta de alimento
ME02859B (me) Formulacija za anti-alfa4beta7 antitelo
MD20070267A (en) Gastroresistant pharmaceutical formulation containing rifaximin
HRP20191477T1 (hr) Farmaceutski sastav s-ketamin hidroklorida
HRP20240086T1 (hr) Režimi za doziranje povezani s injektibilnim formulacijama paliperidona s produljenim oslobađanjem
HRP20121033T1 (hr) Praškasta formulacija za valganciklovir
SE8602722L (sv) Hallbara administreringsformer
HRP20241457T1 (hr) Sredstva za degradaciju porodice cinkovih prstiju ikaros i njihova uporaba
HRP20110713T1 (hr) Postupci liječenja kroničnog virusnog hepatitisa c uz upotrebu ro 113-0830
JP2025084949A5 (OSRAM)
HRP20240074T1 (hr) Režimi za doziranje povezani s injektibilnim formulacijama paliperidona s produljenim oslobađanjem
JP2022522009A5 (OSRAM)
FI3930686T3 (fi) Uusia rautakoostumuksia ja menetelmiä niiden valmistamiseksi ja käyttämiseksi
HRP20240800T1 (hr) Režimi za doziranje povezani s injektibilnim formulacijama paliperidona s produljenim oslobađanjem
IS1834B (is) Lyfjablöndur til inntöku um munn með breytta losun sem innihalda 5-ASA.
HRP20200971T1 (hr) Modulacija djelovanja epidermalnog faktora rasta koji veže heparin u svrhu zacijeljivanja membrane bubnjića
HRP20201683T1 (hr) Imunogeni pripravak namijenjen upotrebi u terapiji
MX2024010596A (es) Composiciones que comprenden 5-metoxi-2-aminoindano (meai) y n-aciletanolaminas y usos de las mismas
HRP20192246T1 (hr) Marker za poremećaje kisele sfingomijelinaze i njegova uporaba
HRP20230823T1 (hr) Derivati deoksi-citidina za uporabu u terapijama raka